Across
- 1. In second line mNSCLC at this point ... is an important treatment goal
- 4. EGFR mutations present an important target that should be ... in any patient before starting therapy
- 5. Third generation TKI's will potentially have their place in ... tumors
- 6. MDPL3280A is a Roche compound in development targetting ...
- 8. Of which drug Dr Cappuzzo noted that it's major advantage may be it's really really good tolerability?
Down
- 2. Rash affects about 66-74% of TKI treated pts among studies, but gefitinib produces more ...
- 3. The available therapies for NSCLC patients who have no identifiable biomarkers have ... and only modest efficacy
- 7. Despite promising pre-clinical data, afatinib was not shown to be effective in patients with ... restistance
- 8. A major toxicity seen with ... is diarrhea